The MOBILE Study—A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain

@article{Bradford2017TheMS,
  title={The MOBILE Study—A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain},
  author={D. Bradford and A. Stirling and E. Ernault and Maggie Liosatos and Katherine Tracy and J. Moseley and P. Blahunka and M. D. Smith},
  journal={Pain Medicine: The Official Journal of the American Academy of Pain Medicine},
  year={2017},
  volume={18},
  pages={2388 - 2400}
}
  • D. Bradford, A. Stirling, +5 authors M. D. Smith
  • Published 2017
  • Medicine
  • Pain Medicine: The Official Journal of the American Academy of Pain Medicine
  • Abstract Objective To evaluate the analgesic efficacy and safety of ASP8477 in patients with peripheral neuropathic pain (PNP). Design Enriched enrollment randomized withdrawal. Setting Centers in Poland (four), Czech Republic (six), and the United Kingdom (two). Subjects Patients aged 18 years or older with PNP resulting from painful diabetic peripheral neuropathy or postherpetic neuralgia. Methods A four-week screening period followed by a single-blind period (six-day dose titration and three… CONTINUE READING
    6 Citations

    Figures, Tables, and Topics from this paper

    References

    SHOWING 1-10 OF 45 REFERENCES